Efficient protection of cells from the genotoxicity of nitrosoureas by the retrovirus-mediated transfer of human O6-methylguanine-DNA methyltransferase using bicistronic vectors with human multidrug resistance gene 1

被引:18
作者
Suzuki, M
Sugimoto, Y
Tsuruo, T
机构
[1] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 170, Japan
[2] Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 113, Japan
关键词
multidrug resistance; nitrosourea resistance; bicistronic retroviral vector; gene therapy; sister chromatid exchange;
D O I
10.1016/S0027-5107(98)00002-5
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Retrovirus-mediated transfer of O-6-methylguanine-DNA methyltransferase (MGMT; E.C. 2.1.1.63) and a human multidrug-resistance gene (MDRI) confers resistance to nitrosoureas and natural product antitumor agents, respectively. In a previous study, we constructed two bicistronic retroviral vectors, Ha-MDR-IRES-MGMT and Ha-MGMT-IRES-MDR, that allow co-expression of the MGMT gene and the MDR1 gene to protect cells from the toxicity of combination chemotherapy, Each cell transduced with Ha-MDR-IRES-MGMT or Ha-MGMT-IRES-MDR showed high-level resistance to vincristine and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU), indicating that the two drug-resistance genes can be functionally co-expressed from these vectors. In the present study, we examined whether the expression of MGMT from these MDR1-MGMT bicistronic retroviral vectors could protect cells from the genotoxicity of nitrosoureas. Three independent Ha-MDR-IRES-MGMT-transduced clones and three independent Ha-MGMT-IRES-MDR-transduced clones of HeLa MR cells showed 12-23-fold and 27-30-fold higher MGMT activity than the parental cells. These clones are more resistant to ACNU mutagenicity measured by the frequency of the emergence of 6-thioguanine-resistant colonies after ACNU treatment over the frequency seen in the parental cells. The ACNU-induced sister chromatid exchange (SCE) was markedly suppressed in these clones. Murine bone marrow cells were transduced with either Ha-MDR-IRES-MGMT or Ha-MGMT-IRES-MDR. Non-selected populations of the transduced cells showed only marginal increases in drug resistance and MGMT activity. Remarkable increase in drug resistance and MGMT activity were observed after a short exposure of the transduced cells to vincristine. The Ha-MDR-IRES-MGMT-transduced, vincristine-selected bone marrow cells showed 27-fold resistance to vincristine, 7-fold resistance to ACNU, and 10-fold higher MGMT activity than the non-transduced, non-selected cells. The Ha-MGMT-IRES-MDR-transduced. vincristine-selected cells showed 8-fold resistance to vincristine. Ih-fold resistance to ACNU and 19-fold higher MGMT activity than the non-transduced, non-selected cells. The rates of ACNU-induced SCE in the vincristine-selected cells were as follows: non-transduced cells (non-selected) and HaMDR-transduced cells > Ha-MDR-IRES-MGMT-transduced cells, Ha-MGMT-IRES-MDR-transduced cells. Again, the only marginal levels of increases in the rates of ACNU-induced SCE were observed in non-selected population of the transduced cells. These results indicate that the MDR1-MGMT bicistronic retrovirus Vectors would be useful to protect normal hematopoietic cells from nitrosourea-induced mutagenesis, and drug-selectable bicistronic constructs would have great advantage over non-selectable vectors. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:133 / 141
页数:9
相关论文
共 31 条
[1]   RETROVIRAL TRANSDUCTION AND EXPRESSION OF THE HUMAN ALKYLTRANSFERASE CDNA PROVIDES NITROSOUREA RESISTANCE TO HEMATOPOIETIC-CELLS [J].
ALLAY, JA ;
DUMENCO, LL ;
KOC, ON ;
LIU, L ;
GERSON, SL .
BLOOD, 1995, 85 (11) :3342-3351
[2]   Retroviral infection is limited by Brownian motion [J].
Chuck, AS ;
Clarke, MF ;
Palsson, BO .
HUMAN GENE THERAPY, 1996, 7 (13) :1527-1534
[3]  
COREY CA, 1990, BLOOD, V75, P337
[4]  
Deisseroth A B, 1994, Hum Gene Ther, V5, P1507
[5]   Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: A pilot trial [J].
Deisseroth, AB ;
Holmes, F ;
Hortobagyi, G ;
Champlin, R .
HUMAN GENE THERAPY, 1996, 7 (03) :401-416
[6]   LEUKEMIA COMPLICATING TREATMENT FOR HODGKINS-DISEASE - THE EXPERIENCE OF THE BRITISH NATIONAL LYMPHOMA INVESTIGATION [J].
DEVEREUX, S ;
SELASSIE, TG ;
HUDSON, GV ;
HUDSON, BV ;
LINCH, DC .
BRITISH MEDICAL JOURNAL, 1990, 301 (6760) :1077-1080
[7]   THE PREVENTION OF THYMIC LYMPHOMAS IN TRANSGENIC MICE BY HUMAN O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE [J].
DUMENCO, LL ;
ALLAY, E ;
NORTON, K ;
GERSON, SL .
SCIENCE, 1993, 259 (5092) :219-222
[8]   Genetic analysis of the multidrug transporter [J].
Gottesman, MM ;
Hrycyna, CA ;
Schoenlein, PV ;
Germann, UA ;
Pastan, I .
ANNUAL REVIEW OF GENETICS, 1995, 29 :607-649
[9]  
GREENBAUM M, 1994, CANCER RES, V54, P4442
[10]   EXPRESSION AND CLONING OF COMPLEMENTARY-DNA FOR A HUMAN ENZYME THAT REPAIRS O-6-METHYLGUANINE IN DNA [J].
HAYAKAWA, H ;
KOIKE, G ;
SEKIGUCHI, M .
JOURNAL OF MOLECULAR BIOLOGY, 1990, 213 (04) :739-747